SOCS7: A Drug Target / Disease Biomarker (G30837)

Target Name: SOCS7

NCBI ID: G30837

SOCS7

SOCS7: A Drug Target / Disease Biomarker

Socs7 is a protein that is expressed in various tissues throughout the body, including the brain, lungs, heart, and kidneys. It is a member of the Src family of proteins, which are known for their ability to initiate and maintain signaling processes in cells. Socs7 has been identified as a potential drug target or biomarker for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the key features of Socs7 is its ability to interact with other proteins that are involved in signaling pathways. This interaction allows Socs7 to play a role in the regulation of a wide range of cellular processes, including cell growth, differentiation, and survival. Socs7 has been shown to be involved in the regulation of several key signaling pathways, including the TGF-β pathway, the PI3K/Akt pathway, and the NF-kappa-B pathway.

Scs7 is also known for its role in the regulation of the immune system. It has been shown to be involved in the development and maintenance of immune cell populations, as well as in the regulation of immune cell function. This involvement in immune regulation makes Socs7 an attractive candidate for potential drugs that are aimed at treating autoimmune disorders.

In addition to its potential as a drug target or biomarker, Socs7 is also of interest as a potential therapeutic agent for a variety of other diseases. For example, it has been shown to be involved in the regulation of cell division and growth, which could make it a useful tool for the treatment of cancer. Socs7 has also been shown to be involved in the regulation of cell survival, which could make it a potential treatment for neurodegenerative diseases.

Socrs7 is also of interest as a potential biomarker for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its ability to interact with other proteins involved in signaling pathways makes it a potential indicator of the presence of these types of diseases. Additionally, its role in the regulation of immune cell function makes it a potential indicator of the presence of autoimmune disorders.

In conclusion, Socs7 is a protein that has been identified as a potential drug target or biomarker for a variety of diseases. Its ability to interact with other proteins involved in signaling pathways makes it a potential indicator of the presence of a wide range of diseases. Further research is needed to fully understand the role of Socs7 in cellular signaling and its potential as a therapeutic agent.

Protein Name: Suppressor Of Cytokine Signaling 7

Functions: Regulates signaling cascades probably through protein ubiquitination and/or sequestration. Functions in insulin signaling and glucose homeostasis through IRS1 ubiquitination and subsequent proteasomal degradation. Inhibits also prolactin, growth hormone and leptin signaling by preventing STAT3 and STAT5 activation, sequestering them in the cytoplasm and reducing their binding to DNA. May be a substrate recognition component of a SCF-like E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins (By similarity)

The "SOCS7 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SOCS7 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets